Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Ali Mansour

Ali Mansour

University of Picardie Jules Verne, France

Title: GFOGER Peptide Inhibits Vascular Calcification In Vitro By Blocking the Osteogenic Switch of Vascular Smooth Muscle Cells

Biography

Biography: Ali Mansour

Abstract

GFOGER Peptide Inhibits Vascular Calcification in Vitro by Blocking the Osteogenic Switch of Vascular Smooth Muscle Cells

 

Ali Mansour

University of Picardie Jules Verne, France

 

Abstract

 

Cardiovascular Diseases (CVDs) are classified on top of the list among different death leading causes in the world. Calcification of the vessel wall accounts for high death rates in patients with many diseases like diabetes, atherosclerosis and Chronic Kidney Disease (CKD). Vascular Calcification (VC) is considered as an active multifaceted pathology that resembles bone physiology and regulated by inductive and inhibitory mechanisms. During the calcification process, Vascular Smooth Muscle Cells (VSMCs) release Extracellular Vesicles (EVs) which act as nucleating foci for crystallization through their interaction with type I collagen, also they undergo active osteogenic process to become osteoblast like cells. Using Surface Plasmon Resonance (SPR) in our previous studies, we successfully identified a specific, six amino acid, collagen sequence (GFOGER) that can be recoginized by integrin expressed on EVs. Recently, we chemically synthesized this GFOGER peptide and we hypothesized if it is able to prevent VC in vitro and ex-vivo. Our results showed that GFOGER peptide decreased Pi-induced calcification, by 66% and 60% in MOVAS-1 and primary human VSMCs respectively. Moreover, GFOGER sequence was effective against aortic rings cultured ex-vivo where it decreased Pi-induced calcification by 91%. At the molecular level, the expression of different osteogenic markers including Runt-related transcription factor 2 (Runx2), Matrix Gla-Protein (MGP), Osteocalcin (OCN) and Tissue Non-Specific Alkaline Phosphatase (TNAP) were downregulated in the presence of the GFOGER peptide. These results suggested that inhibition of VC by GFOGER peptide is in part mediated by a decrease of the osteogenic de-differentiation of vascular smooth muscle cells. Finally, we aim to expand our study in order to check the capacity of GFOGER peptide to inhibit VC on in vivo models.

                                                                            alimansour93@hotmail.com